Ascendis Pharma A/S (ASND)
NASDAQ: ASND · Real-Time Price · USD
157.75
-0.39 (-0.25%)
Apr 24, 2025, 11:22 AM EDT - Market open
Ascendis Pharma Analyst Ratings
Total Analysts
15
Consensus Rating
Strong Buy
Price Target
$202.00
Upside
+28.05%
Ratings History
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| RBC Capital | RBC Capital | Buy Initiates $205 | Buy | Initiates | $205 | +29.95% | Apr 16, 2025 |
| JP Morgan | JP Morgan | Buy Maintains $168 → $200 | Buy | Maintains | $168 → $200 | +26.78% | Mar 18, 2025 |
| Cantor Fitzgerald | Cantor Fitzgerald | Buy Maintains $170 → $200 | Buy | Maintains | $170 → $200 | +26.78% | Feb 25, 2025 |
| Evercore ISI Group | Evercore ISI Group | Buy Maintains $220 → $260 | Buy | Maintains | $220 → $260 | +64.82% | Feb 18, 2025 |
| Goldman Sachs | Goldman Sachs | Strong Buy Maintains $200 → $225 | Strong Buy | Maintains | $200 → $225 | +42.63% | Feb 13, 2025 |
| JP Morgan | JP Morgan | Buy Maintains $167 → $168 | Buy | Maintains | $167 → $168 | +6.50% | Feb 13, 2025 |
| Cantor Fitzgerald | Cantor Fitzgerald | Buy Reiterates $170 | Buy | Reiterates | $170 | +7.77% | Feb 11, 2025 |
| JP Morgan | JP Morgan | Buy Maintains $165 → $167 | Buy | Maintains | $165 → $167 | +5.86% | Jan 29, 2025 |
| UBS | UBS | Strong Buy Initiates $196 | Strong Buy | Initiates | $196 | +24.25% | Jan 7, 2025 |
| TD Cowen | TD Cowen | Strong Buy Maintains $160 → $153 | Strong Buy | Maintains | $160 → $153 | -3.01% | Nov 15, 2024 |
| Wedbush | Wedbush | Buy Reiterates $181 | Buy | Reiterates | $181 | +14.74% | Nov 15, 2024 |
| Oppenheimer | Oppenheimer | Buy Maintains $190 → $180 | Buy | Maintains | $190 → $180 | +14.10% | Nov 15, 2024 |
| Cantor Fitzgerald | Cantor Fitzgerald | Buy Reiterates $170 | Buy | Reiterates | $170 | +7.77% | Nov 15, 2024 |
| Stifel | Stifel | Strong Buy Maintains $200 → $207 | Strong Buy | Maintains | $200 → $207 | +31.22% | Nov 15, 2024 |
| Cantor Fitzgerald | Cantor Fitzgerald | Buy Reiterates $170 | Buy | Reiterates | $170 | +7.77% | Nov 4, 2024 |
| JP Morgan | JP Morgan | Buy Maintains $180 → $174 | Buy | Maintains | $180 → $174 | +10.30% | Oct 23, 2024 |
Upgrade to Pro
Get stock forecasts from Wall Street's highest rated professionals
Get much more with Stock Analysis Pro
- Investment ideas from the top Wall Street analysts
- Unlimited access to all data and tools
- Advanced analyst filtering and sorting options
- Up to 10 years of analyst rating history
Analyst Star Rankings
Our analyst star rankings are based on these four factors
- Success Rate
- The percentage of ratings that are profitable.
- Average Return
- The average percentage return within one year of the rating.
- Rating Count
- The more ratings the analyst has provided, the higher the score.
- Recency
- Ratings provided within the past year contribute to a higher score.